Introduction {#s1}
============

A possible beneficial effect of several vitamins on cognition has been suggested (Beydoun et al., [@B8]). Vitamin D is a steroid hormone that regulates calcium homeostasis. Serum 25-hyrdoxyvitamin D \[25(OH)D\], or vitamin D status, is primarily determined by sunlight skin exposure and secondarily by dietary and supplemental intakes (Buell and Dawson-Hughes, [@B16]). Vitamin D\'s active form (1,25-dihydroxyvitamin D~3~) maintains and stabilizes intracellular signaling pathways involved in memory and cognition (Eyles et al., [@B35]) by increasing *VDR* (Guo et al., [@B38]) and *LRP2* expression in the choroid plexus and helping clear neurotoxic β-amyloids (Deane et al., [@B25]; Carro et al., [@B18]) involved in Alzheimer\'s disease (AD) pathogenesis (Roher et al., [@B66]). Vitamin D-related gene polymorphisms and lower vitamin D intake and status were linked to cognitive decline in epidemiological studies (Annweiler et al., [@B4]; Kuzma et al., [@B47]; Beydoun et al., [@B11]; Goodwill et al., [@B36]) and to markers of brain atrophy and poor white matter integrity (WMI) (Buell et al., [@B17]; Annweiler et al., [@B5], [@B3]; Michos et al., [@B55]; Prager et al., [@B63]; Brouwer-Brolsma et al., [@B15]; Del Brutto et al., [@B26]; Moon et al., [@B58]; Karakis et al., [@B45]; Littlejohns et al., [@B50]; Al-Amin et al., [@B1]). Vitamin D\'s neuroprotective role is likely mediated through the expression of neurotrophins, neurotransmitters, and suppression of inflammatory cytokines (Buell and Dawson-Hughes, [@B16]; Miller, [@B56]; Etgen et al., [@B33]).

Moreover, folate and cobalamin (vitamin B-12) are essential in remethylation of homocysteine (Hcy), a sulfur amino acid with neurotoxic and excitotoxic properties (Kruman et al., [@B46]), yielding methionine (Bottiglieri, [@B14]; Troesch et al., [@B78]). Hcy was recently shown in animal studies to increase tau protein phosphorylation, truncation, and oligomerization, an evidence of direct involvement in AD\'s second pathological hallmark, namely neurofibrillary tangles (NFTs) (Shirafuji et al., [@B72]). Hcy is also converted to cysteine via a vitamin B6-dependent mechanism (Troesch et al., [@B78]). Importantly, folate and cobalamin status were inversely associated with age-related cognitive decline (McCaddon and Miller, [@B51]; Smith and Refsum, [@B73]), with cobalamin further exhibiting direct associations with brain volumes and WMI (Erickson et al., [@B32]; Vogiatzoglou et al., [@B80]; De Lau et al., [@B24]; Pieters et al., [@B61]; Lee et al., [@B49]). A recent trial demonstrated beneficial effects of B-vitamin supplementation on brain magnetic resonance imaging (MRI) measures and cognitive function longitudinally (De Jager et al., [@B23]; Douaud et al., [@B30]). Furthermore, nutritional biomarkers may work synergistically to improve cognitive outcomes (Min and Min, [@B57]; Moretti et al., [@B59]). Since socio-demographic factors relate to both nutrition and cognition (Beydoun et al., [@B10]; Berg et al., [@B7]; McCarrey et al., [@B52]; Weuve et al., [@B83]), studying relations of vitamin D, folate and cobalamin with brain MRI measures, while stratifying by relevant sociodemographic factors is key.

This study examines associations of serum 25(OH)D, folate and cobalamin concentrations with brain volume and WMI among a diverse sample of urban adults, while stratifying by sex, age, race, and poverty status. We hypothesized that first-visit serum 25(OH)D, folate, and cobalamin (and annual rate of change over time) would directly correlate with global and regional gray and white matter (WM and GM) brain volumes and regional WMI measured at one follow-up visit (v~scan~), after a mean follow-up of 5.7 years. Analyses also explored brain regions\' sensitivity to lower vitamin status, differentially by socio-demographic factors.

Methods and Materials {#s2}
=====================

Database
--------

Using area probability sampling, a socio-demographically diverse sample of middle-aged White and African-American urban adults (Age v~1~: 30--64 years) from thirteen contiguous census tracts of Baltimore was recruited into the Healthy Aging of Neighborhoods of Diversity across the Life Span (HANDLS) study (Evans et al., [@B34]). HANDLS is an on-going prospective cohort study, initiated in 2004 by the National Institute on Aging. Potential participants were interviewed and identified by random selections of address listings within each census tract (Evans et al., [@B34]). Participants were invited to join HANDLS if they met the following criteria: (1) between ages 30--64; (2) not currently pregnant; (3) not within 6 months of active cancer treatment; (4) not diagnosed with AIDS; (5) capable of providing written informed consent, thus excluding individuals with probable dementia or very low literacy among others; (6) with a valid government-issued identification and a verifiable address (Evans et al., [@B34]).

Initial examinations were performed in two phases. Phase 1 included the first dietary interview and completion of various demographic and psychosocial scales. Phase 2, performed on Medical Research Vehicles (MRV) parked in participants\' neighborhoods, included the second dietary interview and various physical, medical, and psychosocial examinations, including DXA for bone mineral density and body composition, EKG, intima-media thickness by ultrasound, personal and family health history, physical examination by a physician, physical performance by a brief screening battery, neuropsychological tests, and inventories to assess depressive symptoms (Evans et al., [@B34]). Follow-up visits included largely comparable MRV visits. At visit 2 (v~2~, 2009--2013), blood draw analyzed in the same laboratory facility as for visit 1 yielded similar biochemical and hematological indices that can be studied longitudinally.

Written informed consent was obtained from all participants. Study protocols for HANDLS and HANDLS SCAN were approved by the National Institute on Environmental Health Sciences Institutional Review Board (IRB) of the National Institutes of Health. HANDLS SCAN was also approved by the IRBs of the University of Maryland School of Medicine and the University of Maryland, Baltimore County.

This study analyzed nutritional biomarker data from visit 1 (v~1~: 2004--2009) \[as well as change between v~1~ and v~2~ (2009--2013)\] in relation to follow-up data measured in a sub-sample of N~max~ = 258 participants within the HANDLS SCAN sub-study (v~scan~: 2011--2015) (Waldstein et al., [@B82]). Exposure variables were measured during the Medical Research Vehicle (MRV) examinations (v~1~ and/or v~2~); outcomes were MRI measures of brain volume and WMI at v~scan~ (Waldstein et al., [@B82]). The mean follow-up time between visit 1 and v~scan~ was 5.70 years ± 1.90.

Study Sample
------------

The initial HANDLS cohort included 3,720 participants (30--65 years, AAs and Whites, Phase I, visit 1). We included participants with complete and valid MRI data at follow-up and complete 25(OH)D, folate and cobalamin data at visit 1 and/or visit 2 ([Figure 1](#F1){ref-type="fig"}). Mean ± SD of follow-up time between v~1~ and v~2~ was 4.65 years ± 0.93 (range: 0.4--8.2 years). The final sample was reduced to *N* = 185--186 for vitamin D and *N* = 240 for folate or cobalamin exposures.

![Study participant schematic: HANDLS 2004--2013 and HANDLS-SCAN 2011--2015^a^. 25(OH)D, 25-hydroxyvitamin D; B-12, Vitamin B-12 (cobalamin); dMRI, Diffusion magnetic resonance imaging; HANDLS, Healthy Aging in Neighborhoods of Diversity Across the Life Span; k, average number of repeats; sMRI, Structural/volumetric magnetic resonance imaging. ^a^Visit 1 refers to HANDLS 2004--2009; Visit 2 refers to HANDLS 2009--2013; and HANDLS-SCAN visit (v~scan~) was carried out between 2011 and 2015.](fnagi-12-00140-g0001){#F1}

Brain sMRI
----------

A Siemens Tim-Trio 3.0 Tesla scanner was used for MRI assessments. Magnetization prepared rapid gradient echo (MP-RAGE) was used to perform volumetric measurements for anatomical regions. Volumetric measures were estimated for each region of interest (ROI). Detailed description is provided in [Supplemental Method 1](#SM1){ref-type="supplementary-material"}.

In addition to standard axial T1, T2, FLAIR images, a high-resolution axial T1-weighted MPRAGE (TE = 2.32 ms, TR = 1900 ms, TI = 900 ms, flip angle = 9°, resolution = 256 × 256 × 96, FOV = 230 mm, sl. Thick. = 0.9 mm) of the brain was acquired for structural imaging. Images were used as anatomic references and to extract parameters of regional and whole brain volumes (see [Supplemental Table 1](#SM1){ref-type="supplementary-material"}). This study comprehensively examines brain volumes at ascending segmentation levels.

Brain dMRI
----------

dMRI was obtained using multi-band spin echo EPI sequence with a multi-band acceleration factor of three ([Supplemental Method 1](#SM1){ref-type="supplementary-material"}). Fractional Anisotropy (FA) and trace (TR, aka mean diffusivity or MD) images were computed from tensor images. As intact WM generally allows for more restricted diffusion, higher FA values are indicative of healthier WMI. Summing eigenvalues for diffusion tensor yields MD, with higher values indicative of poorer WMI (Jones, [@B44]). Computed FA and MD images were aligned to a common template space via deformable registration using a standard dMRI template (i.e., EVE Wakana et al., [@B81]). Right and left FA and MD values were averaged for each ROI (see [Supplemental Table 2](#SM1){ref-type="supplementary-material"} for list of ROIs).

Vitamin Status Measures
-----------------------

Participants were asked to fast for ≥8 h prior to the MRV visits, and specimens in volumes of 2 mL serum were collected and frozen at −80°C. Similar procedures were adopted for v~1~ and v~2~ serum folate and cobalamin, measured using chemiluminescence immunoassay[^1^](#fn0001){ref-type="fn"} by Quest Diagnostics, Chantilly, VA[^2^](#fn0002){ref-type="fn"}, and previously validated against other automated methods with coefficient of variation (CV) \< 10% (Owen and Roberts, [@B60]; Ispir et al., [@B39]).

25(OH)D were measured using slightly different methodologies between v~1~ and v~2~. For both visits, blood samples drawn at examination were stored at −80°C. At v~1~, total levels of serum 25(OH)D (in ng/ml; D~2~ and D~3~) were measured using tandem mass spectrometry (interassay CV, 8.6%) at Massachusetts General Hospital, \<60 days later, as recommended for frozen samples (Powe et al., [@B62]). V~2~ 25(OH)D was measured by Quest Diagnostics (Chantilly, VA) using an immunoassay that includes competitive binding of serum 25(OH)D and tracer-labeled 25(OH)D to specific antibody followed by detection and quantitation via chemiluminescence reaction (Diasorin, formerly Incstar), comparable to National Health and Nutrition Examination Surveys 2003--04 assays[^3^](#fn0003){ref-type="fn"} (interassay CV: 4--13%) (Centers for Disease Control Prevention, [@B20]; Diagnostics, [@B29])[^4^](#fn0004){ref-type="fn"}.

Dietary and supplemental intakes of vitamin D, folate and cobalamin were shown to moderately correlate with their corresponding serum biomarkers in HANDLS and national surveys (Beydoun et al., [@B9],[@B12], [@B11]). Moreover, moderate-to-strong correlations were detected for all three biomarkers (Pearson\'s *r* \> 0.30) with annual rates of change also correlating positively with visit 1 values ([Supplemental Method 2](#SM1){ref-type="supplementary-material"}), as did v~1~ vs. v~2~ values for each vitamin in the HANDLS sample: 25(OH)D (*r* = 0.44, *n* = 1,462); folate (*r* = 0.44, *n* = 1,944); cobalamin (*r* = 0.55, *n* = 1,994). We also describe categorical exposures with cutoffs reflecting vitamin insufficiency or deficiency (Snow, [@B74]; Thacher and Clarke, [@B77]; World Health Organization, [@B84]).

Covariates
----------

All models were adjusted for baseline examination age (y), sex (male = 1, female = 0), race (AA = 1, White = 0), self-reported household income either \<125% or ≥125% of the 2004 Health and Human Services poverty guidelines (termed poverty status) (US Department of Health & Human Services, [@B79]), and time (days) between baseline MRV visit and MRI scan visit. Models were independently stratified by age ( ≤ 50 vs. \>50 years), sex, race, or poverty status. Additional covariates were entered in a sensitivity analysis when independently associated with each exposure of interest (see [Supplemental Method 3](#SM1){ref-type="supplementary-material"}).

Statistical Analysis
--------------------

Analyses were conducted using Stata version 16.0 (Stata, [@B75]). First, selected sample characteristics were described, and their means and proportions across key socio-demographic groups were calculated. *T*-test, chi-square, multiple linear, and logistic regression models (Wald tests) were used to determine group differences in distributions of continuous and categorical variables. Second, several sets of analyses were conducted to test main hypotheses, both overall and stratified by age group (≤ 50 vs. \>50 years), sex, race, or poverty status. Ordinary least square regression models included each v~1~ vitamin exposure predicting each MRI measure as the outcome measured at v~scan~, while adjusting for socio-demographic confounders. Ultimately, the most significant adjusted associations with the lowest *p*-values \[or highest --Log~10~(p)\] per analysis were selected, along with their unstandardized (β±SE) and standardized (*b*) effect sizes. Consequently, a looping procedure (*parmsby* command) was applied to generate main parameter estimates, interpreted as change in MRI measure per unit change in serum vitamin biomarker for β and fraction of a SD change in MRI measure per 1 SD change in that biomarker for *b*, which was moderate-to-strong if \>0.20, and weak-to-moderate if between 0.10 and 0.20. Four separate analyses were conducted based on MRI variable groupings. The first analysis included total brain volume (i.e., WM + GM), WM and GM volumes as the only 3 exposure measures (**Model A**). The second analysis included 8 measures (**Model B**): the combination of WM and GM of the 4 main cortical regions: frontal, temporal, parietal, and occipital lobes. A third analysis included the smaller regions, accounting for bilateral volumes, yielding 142 outcome measures (**Model C**). Finally, dMRI measures were included, after taking the average between the left and right side for FA and MD measures, as done previously (McKay et al., [@B53]). This exploratory approach was conducted previously by at least one other study of vitamin D deficiency and WMI (Moon et al., [@B58]). This resulted in 98 (49 FA and 49 MD) dMRI outcome measures, reflecting WMI (**Model D**).

For uncorrected *p*-values, Type I error \<0.05 was used for significance. To adjust for multiple testing two methods were used: (1) Familywise Bonferroni (error rate) correction (FWER) which adjusted for multiplicity in brain MRI measures, assuming each set of modeling approach (Models A-D and stratification status) applied to each serum vitamin \[25(OH)D, folate and cobalamin\] to be separate hypotheses, (2) false discovery rate (*q*-value) which only considered the four approaches/stratification status as separate hypotheses (i.e., Models A-D, and stratification status), thus combining the 3 vitamin exposures upon correction. Moreover, the top 10 adjusted associations from each analysis were presented if *p*~uncorr~ \< 0.05, showing the main parameter estimate and its standard error (SE), the uncorrected *p*-values, the FDR *q*-values and FWER status (Yes = passed correction, No = did not pass) and the standardized effect size *b*. Top 10 associations were considered statistically significant if passing FWER correction for a specific vitamin, model and stratification status (yes vs. no) at type I error of 0.05. Results with FDR *q*-value \< 0.10 per model and stratification status while failing the FWER criterion were considered a trend. Additionally, when passing FDR *q*-value correction at type I error of 0.10 per vitamin, model and stratification status while failing the FWER criterion, an effect was considered a trend if \|*b\|* ≥0.20. Among selected stratified models (top 10 findings), formal effect modification testing was conducted by including 2-way interaction terms between exposure and each socio-demographic factor in the non-stratified model. A Type I error of 0.10 was used for 2-way interaction terms due to reduced statistical power (Selvin, [@B71]). In addition, the main analyses with v~1~ exposures and minimal socio-demographic adjustment, sensitivity analyses were conducted to examine longitudinal exposures (i.e., annual rate of change between v~1~ and v~2~) and additional adjustments ([Supplemental Methods 2, 3](#SM1){ref-type="supplementary-material"}).

Using R version 3.6.1, selected findings for Model D, were presented using volcano plots (R Foundation for Statistical Computing, [@B64]). These plots display Log~10~(*p*-values) for each set of models against *b* on the X-axis, highlighting findings with larger *b*. For dMRI results, these plots were presented separately for FA and MD, given their expected inverse correlation. Visualization of ROI-specific *b* with standard brain images was carried out using FSLeyes software (Jenkinson and Smith, [@B42]; Jenkinson et al., [@B41]) applied to dMRI results (URL: <https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLeyes>). Only ROIs with uncorrected *p*-value \< 0.05 are presented.

Results {#s3}
=======

Greater serum concentrations of 25(OH)D and folate were observed among Whites relative to AAs, with the reverse pattern observed for cobalamin. All three serum concentrations were consistently higher among "above poverty" participants (vs. below poverty), while only 25(OH)D and folate were higher in those aged \>50 years at v~1~ (vs. ≤ 50 years). Larger total and regional volumes among males, Whites, and those living above poverty (for total and GM volume) were detected compared to their counterparts (*p* \< 0.05). The older group had smaller frontal GM volumes than the younger group, and differences by poverty status were mostly notable for occipital and frontal volumes (GM and WM). After multivariable adjustment, most poverty status differences in volumes became non-significant. For simplicity, only larger ROIs are presented ([Table 1](#T1){ref-type="table"}).

###### 

Study sample characteristics by sex, age group, race and poverty status; HANDLS 2004--2009 and HANDLS-SCAN 2011--2015[^a^](#TN1){ref-type="table-fn"}.

                                                         **Total**                     **Females**                                       **Males**                     **≤50 years**                                                                   **\>50 years**               **White**                                                                       **African-American**         **Below poverty**                                                                     **Above poverty**
  ------------------------------------------------------ ----------------------------- ------------------------------------------------- ----------------------------- ------------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------------------------- ---------------------------- ------------------------------------------------------------------------------------- -----------------------------
                                                         **(*****N*** **=** **240)**   **(*****N*** **=** **135)**                       **(*****N*** **=** **105)**   **(*****N*** **=** **143)**                                                     **(*****N*** **=** **97)**   **(*****N*** **=** **141)**                                                     **(*****N*** **=** **99)**   **(*****N*** **=** **79)**                                                            **(*****N*** **=** **161)**
  **DEMOGRAPHIC FACTORS**                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Sex, % males                                           41.3                          \_\_                                              \_\_                          41.3                                                                            47.4                         44.0                                                                            43.4                         35.4                                                                                  47.8
  Age~v1~                                                47.7 ± 8.9                    47.7 ± 0.8                                        47.9 ± 0.8                    41.6 ± 0.5[^c^](#TN3){ref-type="table-fn"}                                      56.7 ± 0.4                   49.0 ± 0.7[^c^](#TN3){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}   46.1 ± 1.0                   44.3 ± 0.9[^c^](#TN3){ref-type="table-fn"}                                            49.3 ± 0.7
  Race, % AA                                             41.2                          41.5                                              41.0                          46.9[^b^](#TN2){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}         32.0                         \_\_                                                                            \_\_                         56.6[^c^](#TN3){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}               74.5
  \% above poverty                                       67.1                          62.2                                              73.3                          57.3[^c^](#TN3){ref-type="table-fn"}                                            81.4                         74.5^3^                                                                         56.6                         \_\_                                                                                  \_\_
                                                         **(*****N*** **=** **183)**   **(*****N*** **=** **99)**                        **(*****N*** **=** **84)**    **(*****N*** **=** **105)**                                                     **(*****N*** **=** **78)**   **(*****N*** **=** **108)**                                                     **(*****N*** **=** **75)**   **(*****N*** **=** **54)**                                                            **(*****N*** **=** **129)**
  **VITAMIN STATUS (v**~**1**~**)**                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  25(OH)D, *ng/mL*                                       22.3 ± 10.8                   20.9 ± 1.1                                        23.9 ± 1.1                    20.5 ± 1.0[^c^](#TN3){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}   24.7 ± 1.2                   26.7 ± 1.0[^c^](#TN3){ref-type="table-fn"}                                      15.9 ± 0.9                   17.2 ± 1.4[^c^](#TN3){ref-type="table-fn"}                                            24.4 ± 0.9
     Median                                              20.0                          19.0                                              23.0                          19.0                                                                            22.5                         25.5                                                                            15.0                         15.5                                                                                  23.0
     IQR                                                 14.0--31.0                    12.0--30.0                                        16--32.5                      12--29                                                                          16--33                       19.0--34.5                                                                      10.0--19.0                   9.0--21.0                                                                             16.0--33.0
     % \<20                                              37.1                          40.7                                              32,4                          39.2                                                                            34.0                         20.6[^c^](#TN3){ref-type="table-fn"}                                            60.6                         48.1[^c^](#TN3){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}               31.7
     % \<10                                              9.6                           12.6                                              5.7                           14.0[^c^](#TN3){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}         3.1                          2.8[^c^](#TN3){ref-type="table-fn"}                                             19.2                         20.3[^c^](#TN3){ref-type="table-fn"}                                                  4.4
                                                         **(*****N*** **=** **240)**   **(*****N*** **=** **135)**                       **(*****N*** **=** **105)**   **(*****N*** **=** **143)**                                                     **(*****N*** **=** **97)**   **(*****N*** **=** **141)**                                                     **(*****N*** **=** **99)**   **(*****N*** **=** **79)**                                                            **(*****N*** **=** **161)**
  Serum folate, ng/mL                                    15.0 ± 6.3                    15.0 ± 0.6                                        15.0 ± 0.6                    13.5 ± 0.5[^c^](#TN3){ref-type="table-fn"}                                      17.4 ± 0.6                   16.0 ± 0.5[^c^](#TN3){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}   13.6 ± 0.6                   13.1 ± 0.6[^c^](#TN3){ref-type="table-fn"}                                            16.1 ± 0.5
     Median                                              14.3                          14.7                                              14.2                          12.6                                                                            17.9                         15.4                                                                            12.7                         12.5                                                                                  15.2
     IQR                                                 9.5--20.6                     9.2--20.6                                         9.5--20.5                     8.9--17.1                                                                       12.2--22.5                   10.6--21.3                                                                      8.5--17.5                    8.6--17.1                                                                             10.6--21.3
     % \<6                                               6.3                           7.4                                               4.8                           8.4                                                                             3.1                          4.3                                                                             9.1                          7.6                                                                                   5.6
  Serum B-12, *pg/mL*                                    518.7 ± 239.7                 535.4 ± 23.0                                      497.2 ± 19.3                  502.7 ± 18.3                                                                    542.3 ± 27.1                 488.0 ± 19.7[^b^](#TN2){ref-type="table-fn"}                                    562.6 ± 24.3                 475.3 ± 19.2[^b^](#TN2){ref-type="table-fn"}                                          540.0 ± 20.9
     Median                                              463.0                         464.0                                             456.0                         460.0                                                                           464.0                        438.0                                                                           521.0                        455                                                                                   467.0
     IQR                                                 360.0--626.5                  374.0--631.0                                      347--623.0                    359--571                                                                        362.0--644.0                 339.0--571.0                                                                    390.0--679.0                 338.0--457.0                                                                          364.0--644.0
     % \<200                                             0.42                          \_\_                                              \_\_                          \_\_                                                                            \_\_                         \_\_                                                                            \_\_                         \_\_                                                                                  \_\_
  **BRAIN VOLUMES (v**~**scan**~**)**, ***mm**^**3**^*                                                                                                                                                                                                                                                                                                                                                                                                                                 
  Total brain volume                                     970,454 ± 104,344             921,280 ± 6,311[^c^](#TN3){ref-type="table-fn"}   1,033,677 ± 10,198            978,724 ± 8,702                                                                 958,261 ± 10,569             989,978 ± 8,947[^c^](#TN3){ref-type="table-fn"}                                 942,645 ± 9,587              951,587 ± 11,157[^b^](#TN2){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}   979,711 ± 8,343
  Gray matter                                            513,545 ± 5,6152              488,776 ± 3,542[^c^](#TN3){ref-type="table-fn"}   545,391 ± 5,558               519,446 ± 4,752                                                                 504,846 ± 5,510              526,576 ± 4,657[^c^](#TN3){ref-type="table-fn"}                                 494,985 ± 5,249              502,325 ± 6,015[^b^](#TN2){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}    518,559 ± 4,485
  White matter                                           456,908 ± 51,582              432,504 ± 3,111[^c^](#TN3){ref-type="table-fn"}   488,286 ± 5,036               459,278 ± 4,214                                                                 453,414 ± 5,417              463,402 ± 4,531[^b^](#TN2){ref-type="table-fn"}                                 447,660 ± 4,720              448,261 ± 5,506                                                                       461,151 ± 4,134
  Gray matter: Frontal                                   179,001 ± 20,690              170,642 ± 1,350[^c^](#TN3){ref-type="table-fn"}   189,748 ± 2,092               181,228 ± 1,788[^b^](#TN2){ref-type="table-fn"}                                 175,421 ± 1,947              183,082 ± 1,772[^c^](#TN3){ref-type="table-fn"}                                 173,188 ± 1890               175,430 ± 2,166[^b^](#TN2){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}    180,752 ± 1,671
  Gray matter: temporal                                  98,813 ± 11,598               93,343 ± 740[^c^](#TN3){ref-type="table-fn"}      105,847 ± 1,091               99,454 ± 982                                                                    97,869 ± 1,154               101,081 ± 956[^c^](#TN3){ref-type="table-fn"}                                   95,584 ± 1,128               96,870 ± 1255                                                                         99,767 ± 924
  Gray matter: occipital                                 68,691 ± 9,035                65,145 ± 607[^c^](#TN3){ref-type="table-fn"}      73,251 ± 907                  69,202 ± 765                                                                    67,937 ± 900                 71,392 ± 730[^c^](#TN3){ref-type="table-fn"}                                    64,846 ± 817                 66,637 ± 962[^c^](#TN3){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}       69,699 ± 718
  Gray matter: parietal                                  87,585 ± 11,259               83,786 ± 787[^c^](#TN3){ref-type="table-fn"}      92,470 ± 1,158                88,950 ± 930[^b^](#TN2){ref-type="table-fn"}                                    85,572 ± 1138                90,446 ± 926[^c^](#TN3){ref-type="table-fn"}                                    83,510 ± 1,044               85,916 ± 1,243                                                                        88,404 ± 891
  White matter: Frontal                                  186,294 ± 21,618              176,870 ± 1,353[^c^](#TN3){ref-type="table-fn"}   198,412 ± 2,164               187,094 ± 1,791                                                                 185,115 ± 2,230              188,256 ± 1,888                                                                 183,500 ± 2,031              182,321 ± 2,275[^b^](#TN2){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}    188,243 ± 1,739
  White matter: temporal                                 104,302 ± 12,020              98,399 ± 688[^c^](#TN3){ref-type="table-fn"}      111,893 ± 1,181               104,782 ± 969[^e^](#TN5){ref-type="table-fn"}                                   103,596 ± 1,284              106,1044 ± 1,050[^c^](#TN3){ref-type="table-fn"}                                101,750 ± 1,107              102,559 ± 1,268                                                                       105,158 ± 970
  White matter: occipital                                45,860 ± 6,113                43,155 ± 414[^c^](#TN3){ref-type="table-fn"}      49,338 ± 571                  46,394 ± 509[^e^](#TN5){ref-type="table-fn"}                                    45,073 ± 619                 46,879 ± 538[^c^](#TN3){ref-type="table-fn"}                                    44,410 ± 543                 44,775 ± 627[^b^](#TN2){ref-type="table-fn"}^,^[^d^](#TN4){ref-type="table-fn"}       46,392 ± 497
  White matter: parietal                                 90,621 ± 11,436               85,721 ± 765[^c^](#TN3){ref-type="table-fn"}      96,920 ± 1,101                91,074 ± 939                                                                    89,951 ± 1,193               92,253 ± 1,018[^b^](#TN2){ref-type="table-fn"}                                  88,295 ± 1,009               89,171 ± 1,270                                                                        91,332 ± 904

*25(OH)D, 25-hydroxivitamin D; Age~v1~, age measured at HANDLS visit 1 (2004--2009); HANDLS, Healthy Aging in Neighborhoods of Diversity Across the Life Span; HANDLS-SCAN, Brain magnetic resonance imaging scan ancillary study of HANDLS; IQR, Interquartile range (25th−75th percentile); v~1~, visit 1 of HANDLS (2004--2009); v~scan~, HANDLS-SCAN visit (2011--2015)*.

*Values are Mean ± SD for totals and Mean ± SE for stratum-specific, or %. For 25(OH)D, folate and vitamin B-12, medians and inter-quartile ranges (IQR) were also provided. N = 183 for 25(OH)D analysis. The sample is that of HANDLS participants with complete visit 1 folate/B-12 measures and sMRI data \[N = 240 for most analysis; N = 183 for 25(OH)D\]. See methods for cutoffs chosen for each vitamin. Cobalamin deficiency analysis yielded only 1 participant below the 200 pg/mL cutoff. Thus, stratified analysis was not conducted*.

*P \< 0.05*.

*P \< 0.010 for null hypothesis of no difference by sex, age group, race, or poverty status, t-test (continuous variables), and chi-squared test (categorical variables)*.

*P ≥ 0.05 after adjustment for remaining covariates, multiple linear regression (continuous variables), multiple logistic regression (categorical variables)*.

*P \< 0.05 after adjustment for remaining covariates, multiple linear regression (continuous variables), multiple logistic regression (categorical variables)*.

Top 10 adjusted associations with uncorrected *p* \< 0.05 from ordinary least square brain scan-wide analyses are presented in [Tables 2](#T2){ref-type="table"}--**4**, [Supplemental Tables 3--5](#SM1){ref-type="supplementary-material"}, and [Figure 2](#F2){ref-type="fig"}. Among significant findings (FWER \<0.05) in the main analysis ([Table 2](#T2){ref-type="table"}), serum 25(OH)D was directly associated with larger WM volumes \[overall (β = +910 ± 336, *p* = 0.007, *q* = 0.067, passed FW Bonferroni correction), effect size *b* = 0.19\], with a stronger effect size among men (*b* = 0.41). This association was specific to occipital and parietal WM, with a moderate effect size (*b* = +0.23--0.25, *q* \< 0.05, passed FW Bonferroni correction) in the overall sample, men and the older group. A trend toward a direct association was also detected between 25(OH)D and total brain volume in the overall sample, in men and those in the older group. Among trends (*q*-value \< 0.10), temporal and occipital WM volumes were directly associated with 25(OH)D, in Whites and individuals living above poverty, respectively. Most of these 25(OH)D *vs*. larger ROIs associations were not altered when additional covariates were entered in a sensitivity analysis and were comparable in the sensitivity analysis for annual rate of change in 25(OH)D ([Table 2](#T2){ref-type="table"}). Higher cobalamin exhibited a trend association with larger total brain, total GM, frontal and occipital GM volumes in the overall sample (*q*-value \< 0.10), becoming null after adjustment for 25(OH)D and other covariates (see [Supplemental Method 2](#SM1){ref-type="supplementary-material"}). In the sensitivity analysis ([Supplemental Table 3](#SM1){ref-type="supplementary-material"}), notable associations that survived addition of covariates included 25(OH)D over time increase in relation to larger TOTAL (overall, \>50), WM (overall, males, \>50 years), and GM (males) volumes, mostly in occipital and parietal regions.

###### 

Top 10 adjusted associations from models A (total, GM, WM) and B (regional GM, WM) vs. visit 1 exposures: serum 25(OH)D, folate and cobalamin (overall and stratified analysis) with uncorrected *P* \< 0.05: ordinary least square brain scan-wide analyses on HANDLS 2004--2009 and HANDLS-SCAN 2011--2015[^a^](#TN6){ref-type="table-fn"}.

                   **Outcome (v~**scan**~)**   **Outcome description**      **Exposure (v~**1**~)**   **Stratum**   **(*N*)**   **β**                                       **(*SE*)**   ***P*~**uncorr**~**   **Standardized Beta (b)**   ***q*-value**                           **Passes FW Bonferroni correction**   **Standardized Beta (b): SA[^b^](#TN7){ref-type="table-fn"}**   ***P*~**uncorr**~: SA**
  ---------------- --------------------------- ---------------------------- ------------------------- ------------- ----------- ------------------------------------------- ------------ --------------------- --------------------------- --------------------------------------- ------------------------------------- --------------------------------------------------------------- -------------------------
  **MODEL A**                                                                                                                                                                                                                                                                                                                                                                            
                   **WM**                      **White matter**             **25(OH)D**               **\_\_**      **(186)**   **+910**                                    **(336)**    **0.007**             **+0.19**                   **0.067**                               **Yes**                               **+0.18**                                                       **0.017**
  Overall          TOTALBRAIN                  Total brain volume           25(OH)D                   \_\_          \(186\)     +1554                                       \(659\)      0.019                 +0.16                       0.087[^d^](#TN9){ref-type="table-fn"}   No                                    +0.15                                                           0.033
  **Stratified**   **WM**                      **White matter**             **25(OH)D**               **Males**     **(87)**    **+2054**[^c^](#TN8){ref-type="table-fn"}   **(599)**    **0.001**             **+0.41**                   **0.069**                               **Yes**                               **+0.43**                                                       **0.002**
                   WM                          White matter                 25(OH)D                   \>50 years    \(80\)      +1500[^c^](#TN8){ref-type="table-fn"}       \(470\)      0.002                 +0.31                       0.076[^d^](#TN9){ref-type="table-fn"}   No                                    +0.25                                                           0.017
                   TOTALBRAIN                  Total brain volume           25(OH)D                   Males         \(87\)      +3537[^c^](#TN8){ref-type="table-fn"}       \(1180\)     0.004                 +0.34                       0.087[^d^](#TN9){ref-type="table-fn"}   No                                    +0.38                                                           0.005
                   TOTALBRAIN                  Total brain volume           25(OH)D                   \>50 years    \(80\)      +2551[^c^](#TN8){ref-type="table-fn"}       \(891\)      0.005                 +0.28                       0.098[^d^](#TN9){ref-type="table-fn"}   No                                    +0.22                                                           0.023
                   GM                          Gray matter                  25(OH)D                   Males         \(87\)      +1481                                       \(630\)      0.021                 +0.26                       0.29                                    No                                    +0.30                                                           0.022
                   WM                          White matter                 25(OH)D                   AP            \(132\)     +930                                        \(406\)      0.024                 +0.18                       0.29                                    No                                    ***+0.16***                                                     ***0.088***
                   GM                          Gray matter                  25(OH)D                   \>50 years    \(80\)      +1051                                       \(471\)      0.029                 +0.22                       0.29                                    No                                    ***+0.19***                                                     ***0.052***
                   GM                          Gray matter                  B-12                      AP            \(161\)     +28                                         \(13\)       0.034                 +0.13                       0.29                                    No                                    +0.08                                                           0.26
                   TOTALBRAIN                  Total brain volume           25(OH)D                   AP            \(132\)     +1663                                       \(789\)      0.037                 +0.16                       0.29                                    No                                    ***+0.15***                                                     ***0.085***
                   TOTALBRAIN                  Total brain volume           B-12                      AP            \(161\)     52                                          \(26\)       0.044                 +0.13                       0.29                                    No                                    +0.07                                                           0.31
  **MODEL B**                                                                                                                                                                                                                                                                                                                                                                            
  **Overall**      **OCCIPITAL_WM**            **Occipital white matter**   **25(OH)D**               **\_\_**      **(186)**   **+140**                                    **(40)**     **5.2e-04**           **+0.25**                   **0.012**                               **Yes**                               **+0.24**                                                       **0.001**
                   **PARIETAL_WM**             **Parietal white matter**    **25(OH)D**               **\_\_**      **(186)**   **+251**                                    **(77)**     **1.5e-03**           **+0.23**                   **0.017**                               **Yes**                               **+0.22**                                                       **0.004**
                   PARIETAL_GM                 Parietal gray matter         25(OH)D                   \_\_          \(186\)     +191                                        (74.9)       1.2e-02               +0.18                       0.086[^d^](#TN9){ref-type="table-fn"}   No                                    +0.18                                                           0.016
                   FRONTAL_GM                  Frontal gray matter          B-12                      \_\_          \(240\)     +11.2                                       \(5\)        1.6e-02               +0.13                       0.086[^d^](#TN9){ref-type="table-fn"}   No                                    +0.07                                                           0.27
                   OCCIPITAL_GM                Occipital gray matter        B-12                      \_\_          \(240\)     +4.8                                        (2.0)        1.8e-02               +0.13                       0.086[^d^](#TN9){ref-type="table-fn"}   No                                    +0.10                                                           0.12
                   TEMPORAL_WM                 Temporal white matter        25(OH)D                   \_\_          \(186\)     +178                                        \(77\)       2.2e-02               +0.16                       0.089[^d^](#TN9){ref-type="table-fn"}   No                                    +0.15                                                           0.039
                   FRONTAL_WM                  Frontal white matter         25(OH)D                   \_\_          \(186\)     +309                                        \(149\)      3.9e-02               +0.15                       0.13                                    No                                    +0.13                                                           0.079
  **Stratified**   **OCCIPITAL_WM**            **Occipital white matter**   **25(OH)D**               **Males**     **(87)**    **+261[^c^](#TN8){ref-type="table-fn"}**    **(67)**     **2.1e-04**           **+0.44**                   **0.020**                               **Yes**                               **+0.45**                                                       **0.001**
                   **PARIETAL_WM**             **Parietal white matter**    **25(OH)D**               **Males**     **(87)**    **+486[^c^](#TN8){ref-type="table-fn"}**    **(129)**    **3.1e-04**           **+0.44**                   **0.020**                               **Yes**                               **+0.45**                                                       **0.001**
                   **OCCIPITAL_WM**            **Occipital white matter**   **25(OH)D**               **\>50**      **(80)**    **+205**                                    **(54)**     **3.2e-04**           **+0.37**                   **0.020**                               **Yes**                               **+0.27**                                                       **0.005**
                   **PARIETAL_WM**             **Parietal white matter**    **25(OH)D**               **\>50**      **(80)**    **+393[^c^](#TN8){ref-type="table-fn"}**    **(108)**    **5.4e-04**           **+0.37**                   **0.020**                               **Yes**                               **+0.32**                                                       **0.004**
                   OCCIPITAL_WM                Occipital white matter       25(OH)D                   AP            \(132\)     +156                                        \(48\)       1.3e-03               +0.25                       0.050[^d^](#TN9){ref-type="table-fn"}   No                                    +0.26                                                           0.004
                   OCCIPITAL_WM                Occipital white matter       25(OH)D                   Whites        \(109\)     +155                                        \(49\)       2.2e-03               +0.25                       0.063[^d^](#TN9){ref-type="table-fn"}   No                                    +0.28                                                           0.002
                   FRONTAL_WM                  Frontal white matter         25(OH)D                   Males         \(87\)      +826**[^c^](#TN8){ref-type="table-fn"}**    \(262\)      2.3e-03               +0.38                       0.063[^d^](#TN9){ref-type="table-fn"}   No                                    +0.42                                                           0.003
                   TEMPORAL_WM                 Temporal white matter        25(OH)D                   \>50          \(80\)      +326**[^c^](#TN8){ref-type="table-fn"}**    \(108\)      3.5e-03               +0.29                       0.084[^d^](#TN9){ref-type="table-fn"}   No                                    +0.23                                                           0.024
                   TEMPORAL_GM                 Temporal gray matter         FOL                       Whites        \(109\)     −354**[^c^](#TN8){ref-type="table-fn"}**    \(123\)      4.7e-03               −0.20                       0.10                                    No                                    −0.26                                                           0.004
                   FRONTAL_GM                  Fontal gray matter           B-12                      AP            \(132\)     +13.4                                       (5.1)        9.7e-03               +0.17                       0.18                                    No                                    +0.09                                                           0.22

*25(OH)D, 25-hydroxyvitamin D; AP, Above poverty; B-12, serum cobalamin (vitamin B-12); FDR, False Discovery Rate; FOL, serum folate; FWER, FamilyWise Error Rate; GM, Gray Matter; SA, Sensitivity Analysis; SE, Standard Error; WM, White Matter*.

*Values are adjusted linear regression coefficients β with associated SE, standardized beta, uncorrected p-values, corrected q-values (false discovery rate) and results of sensitivity analysis. (N) is the sample size in each analysis. Bolded rows correspond to statistically significant associations after correction for multiple testing, FWER \<0.05*.

*Based on a sensitivity analysis further adjusting for selected socio-demographic, lifestyle and health-related factors after screening using machine learning techniques (see [Supplemental Methods 2](#SM1){ref-type="supplementary-material"}). Note that for visit 1 25(OH)D, no additional covariates were selected. For Folate and B-12 a reduced set of additional covariates were included and are listed in [Supplemental Methods 2](#SM1){ref-type="supplementary-material"}*.

*P \< 0.10 for null hypothesis that exposure × stratifying variable 2-way interaction term is =0 in the unstratified model with exposure and socio-demographic factors included as main effects*.

*Finding considered a trend for passing FDR q-value correction at type I error of 0.10 per vitamin, model and stratification status while failing the FWER criterion, due to a standardized effect size (in absolute value) ≥0.20*.

![ROI-wide brain dMRI association with v~1~ serum 25(OH)D, folate and cobalamin in total population: volcano plots and brain image visualization for HANDLS 2004--2009 and HANDLS-SCAN 2011--2015^a,\ b^. ^a^Volcano plots display Log~10~(*p*-values) for each set of models against the standardized effect (b) on the X-axis, highlighting findings with larger effect sizes. Associations with *P* \< 0.05 are presented in red, whereas those with both *P* \< 0.05 and effect size in absolute value \>0.20 are presented in green. ^b^Brain visualization using FSLeyes program is focused on standardized effect sizes (b) and direction, with negative effects (*b* \< 0) shown in cold colors and positive effects (*b* \> 0) shown in warmer colors. The range is between −0.3 and +0.3 with lighter colors indicating stronger effects in either direction. Only ROIs with uncorrected *p*-value \< 0.05 are presented.](fnagi-12-00140-g0002){#F2}

For smaller ROI volumetric analysis ([Table 3](#T3){ref-type="table"}), 25(OH)D was significantly linked to larger left occipital pole volumes (FWER \< 0.05, *b* = +0.35), overall and among individuals living above poverty, with a trend among men and Whites. Other stratum-specific trends were noted between 25(OH)D and right post-central gyrus volume in men, and parietal and occipital WM volume in men and the older group. Folate\'s relation with right temporal pole was detected among Whites (*p* \< 0.05, *q* \< 0.10 per vitamin, *b* = −0.34). In the sensitivity analysis ([Supplemental Table 4](#SM1){ref-type="supplementary-material"}), among top 10 findings, over-time increase in cobalamin was associated with larger left orbital part of the inferior frontal gyrus (*b* = +0.24, *p* = 0.001). The inverse relationship between longitudinal increase in folate and the right temporal pole volume among Whites was attenuated with additional model adjustment for potential confounders (*p*~full~ = 0.074). The volume of the anterior limb of the internal capsule (ALIC) was directly associated with rate of increase 25(OH)D in a bi-lateral manner, among older individuals.

###### 

Top 10 adjusted associations from model C, small sMRI regions vs. visit 1 exposures: serum 25(OH)D, folate and cobalamin (overall and stratified analysis) with uncorrected *P* \< 0.05: ordinary least square brain scan-wide analyses on HANDLS 2004--2009 and HANDLS-SCAN 2011--2015[^a^](#TN10){ref-type="table-fn"}.

  **Outcome (v~**scan**~)**          **Outcome description**                                **Exposure (v~**1**~)**   **Stratum**   **(*N*)**   **β**                                        **(*SE*)**   ***P***       **Standardized Beta (b)**   ***q*-value**                            **Passes FW Bonferroni correction**   **Standardized Beta (b): SA[^b^](#TN11){ref-type="table-fn"}**   ***P*~**uncorr**~: SA**
  ---------------------------------- ------------------------------------------------------ ------------------------- ------------- ----------- -------------------------------------------- ------------ ------------- --------------------------- ---------------------------------------- ------------------------------------- ---------------------------------------------------------------- -------------------------
  **OVERALL**                                                                                                                                                                                                                                                                                                                                                                                       
  **Left_OCP_occipital_pole**        **Left occipital pole**                                **25(OH)D**               **\_\_**      **(186)**   **+15.70**                                   **(3.83)**   **6.3e-05**   **+0.31**                   **0.026**                                **Yes**                               **+0.27**                                                        **\<0.001**
  occipital_lobe_WM_left             Occipital lobe, white matter, left                     25(OH)D                   \_\_          \(186\)     +76.8                                        (20.7)       2.9e-04       +0.26                       0.061[^d^](#TN13){ref-type="table-fn"}   No                                    +0.26                                                            \<0.001
  Right_PoG_post-central_gyrus       Post-central gyrus, right                              25(OH)D                   \_\_          \(186\)     +34.8                                        (9.7)        4.3e-04       +0.27                       0.061[^d^](#TN13){ref-type="table-fn"}   No                                    +0.27                                                            0.001
  parietal_lobe_WM_right             Parietal lobe, white matter, right                     25(OH)D                   \_\_          \(186\)     +127.9                                       (38.1)       9.8e-04       +0.24                       0.10[^d^](#TN13){ref-type="table-fn"}    No                                    +0.23                                                            0.002
  Left_PoG_post-central_gyrus        Post-central gyrus, left                               25(OH)D                   \_\_          \(186\)     +34.1                                        (10.4)       1.3e-03       +0.25                       0.11[^d^](#TN13){ref-type="table-fn"}    No                                    +0.25                                                            0.002
  Right_TrIFG_triangular_part_of_t   Triangular part of the inferior frontal gyrus, right   B-12                      \_\_          \(240\)     +0.45                                        (0.14)       2.2e-03       +0.20                       0.13                                     No                                    +0.19                                                            0.017
  parietal_lobe_WM_left              Parietal lobe, white matter, left                      25(OH)D                   \_\_          \(186\)     +123.4                                       (40.4)       3.1e-03       +0.22                       0.13[^d^](#TN13){ref-type="table-fn"}    No                                    +0.21                                                            0.007
  occipital_lobe_WM_right            Occipital lobe, white matter, right                    25(OH)D                   \_\_          \(186\)     +63.6                                        (21.1)       3.0e-03       +0.21                       0.13[^d^](#TN13){ref-type="table-fn"}    No                                    +0.21                                                            0.005
  Right_TMP_temporal_pole            Right temporal pole                                    FOL                       \_\_          \(240\)     −35.5                                        (11.9)       2.7e-03       −0.19                       0.13                                     No                                    −0.22                                                            0.010
  Anterior insula, right             Right_AIns_anterior_insula                             B-12                      \_\_          \(240\)     +0.36                                        (0.12)       3.2e-03       +0.17                       0.13                                     No                                    +0.13                                                            0.071
  **STRATIFIED**                                                                                                                                                                                                                                                                                                                                                                                    
  **Left_OCP_occipital_pole**        **Left occipital pole**                                **25(OH)D**               **AP**        **(132)**   **+19.0[^c^](#TN12){ref-type="table-fn"}**   **(4.3)**    **2.0e-05**   **+0.35**                   **0.07**                                 **Yes**                               **+0.32**                                                        **\<0.001**
  Right_TMP_temporal_pole            Right temporal pole                                    FOL                       Whites        \(141\)     −63.9[^c^](#TN12){ref-type="table-fn"}       (15.2)       4.8e-05       −0.34                       0.08[^d^](#TN13){ref-type="table-fn"}    No                                    −0.42                                                            \<0.001
  Left_OCP_occipital_pole            Left occipital pole                                    25(OH)D                   Men           \(87\)      +24.0                                        (5.8)        8.0e-05       +0.45                       0.09[^d^](#TN13){ref-type="table-fn"}    No                                    +0.46                                                            \<0.001
  Left_OCP_occipital_pole            Left occipital pole                                    25(OH)D                   Whites        \(109\)     +17.7                                        (4.5)        1.6e-04       +0.33                       0.11[^d^](#TN13){ref-type="table-fn"}    No                                    +0.31                                                            0.001
  Right_PoG_post-central_gyrus       Right post-central gyrus                               25(OH)D                   Men           \(87\)      +64.4[^c^](#TN12){ref-type="table-fn"}       (16.6)       1.6e-04       +0.43                       0.13[^d^](#TN13){ref-type="table-fn"}    No                                    +0.47                                                            0.001
  Parietal_lobe_WM_right             Right parietal lobe, White matter                      25(OH)D                   Men           \(87\)      +242.6[^c^](#TN12){ref-type="table-fn"}      (63.4)       2.6e-04       +0.45                       0.13[^d^](#TN13){ref-type="table-fn"}    No                                    +0.46                                                            0.001
  occipital_lobe_WM_left             Occipital lobe, white matter, left                     25(OH)D                   \>50          \(80\)      +107.7                                       (28.0)       3.4e-04       +0.37                       0.14[^d^](#TN13){ref-type="table-fn"}    No                                    +0.28                                                            0.004
  parietal_lobe_WM_left              Parietal lobe, white matter, left                      25(OH)D                   \>50          \(80\)      +201.8[^c^](#TN12){ref-type="table-fn"}      (53.6)       3.4e-04       +0.39                       0.14[^d^](#TN13){ref-type="table-fn"}    No                                    +0.34                                                            0.003
  occipital_lobe_WM_right            Occipital lobe, white matter, right                    25(OH)D                   Men           \(87\)      +132.3[^c^](#TN12){ref-type="table-fn"}      (35.9)       4.1e-04       +0.43                       0.14[^d^](#TN13){ref-type="table-fn"}    No                                    +0.44                                                            0.001
  Right_PHG_parahippocampal_gyrus    Right parahippocampal gyrus                            FOL                       Whites        \(141\)     −20.6[^c^](#TN12){ref-type="table-fn"}       (5.7)        4.2e-04       −0.27                       0.14                                     No                                    −0.38                                                            \<0.001

*25(OH)D, 25-hydroxyvitamin D; AP, Above poverty; B-12, serum cobalamin (vitamin B-12); FDR, False Discovery Rate; FOL, serum folate; FWER, FamilyWise Error Rate; GM, Gray Matter; SA, Sensitivity Analysis; SE, Standard Error; WM, White Matter*.

*Values are adjusted linear regression coefficients β with associated SE, standardized beta, uncorrected p-values, corrected q-values (false discovery rate) and results of sensitivity analysis. (N) is the sample size in each analysis. Bolded rows correspond to statistically significant associations after correction for multiple testing, FWER \< 0.05*.

*Based on a sensitivity analysis further adjusting for selected socio-demographic, lifestyle and health-related factors after screening using machine learning techniques (see [Supplemental Methods 2](#SM1){ref-type="supplementary-material"}). Note that for visit 1 25(OH)D, no additional covariates were selected. For Folate and B-12 a reduced set of additional covariates were included and are listed in [Supplemental Methods 2](#SM1){ref-type="supplementary-material"}*.

*P \< 0.10 for null hypothesis that exposure × stratifying variable 2-way interaction term is =0 in the unstratified model with exposure and socio-demographic factors included as main effects*.

*Finding considered a trend for passing FDR q-value correction at type I error of 0.10 per vitamin, model and stratification status while failing the FWER criterion, due to a standardized effect size (in absolute value) ≥0.20*.

In the dMRI analysis ([Table 4](#T4){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}), both folate and 25(OH)D were significantly associated with better WMI, overall, in two key regions: Lower MD in the ALIC region for folate (*b* = −0.23, FWER \< 0.05), and higher FA in the cingulum (cingulate gyrus) for 25(OH)D (FWER \< 0.05, *b* = +0.31). No significant or trend associations were detected between vitamin B-12 and dMRI measures. In the sensitivity analysis ([Supplemental Table 5](#SM1){ref-type="supplementary-material"}), results for 25(OH)D, but not folate, were comparable to v~1~ exposures with additional notable positive associations found between rate of increase in 25(OH)D and the cingulum (Hippocampus) FA, which was statistically significant overall (FWER \< 0.05, *b* = +0.23).

###### 

Top 10 adjusted associations from model D, bilateral means of MD and FA from dMRI vs. visit 1 exposures: serum 25(OH)D, folate and cobalamin (overall and stratified analysis) with uncorrected *P* \< 0.05: ordinary least square brain scan-wide analyses on HANDLS 2004--2009 and HANDLS-SCAN 2011--2015[^a^](#TN14){ref-type="table-fn"}.

  **Outcome (v~**scan**~)**   **Outcome description**                                                        **Exposure (v~**1**~)**   **Stratum**   **(*N*)**   **β**                                         **(*SE*)**       ***P***       **Standardized Beta (b)**   ***q*-value**                                **Passes FW Bonferroni correction**   **Standardized Beta (b): SA[^b^](#TN15){ref-type="table-fn"}**   ***P*~**uncorr**~: SA**
  --------------------------- ------------------------------------------------------------------------------ ------------------------- ------------- ----------- --------------------------------------------- ---------------- ------------- --------------------------- -------------------------------------------- ------------------------------------- ---------------------------------------------------------------- -------------------------
  **OVERALL**                                                                                                                                                                                                                                                                                                                                                                                                                 
  **alic_b\_tr**              **Anterior limb of the internal capsule, Mean diffusivity, bilateral mean**    **FOL**                   **\_\_**      **(240)**   **−5.64e-06**                                 **(1.56e-06)**   **3.8e-04**   **−0.23**                   **0.074[^d^](#TN17){ref-type="table-fn"}**   **Yes**                               **−0.26**                                                        **0.003**
  **cgc_b\_fa**               **Cingulum (Cingulate Gyrus), fractional anisotropy, bilateral mean**          **25(OH)D**               **\_\_**      **(185)**   **+0.0007**                                   **(0.0002)**     **4.1e-04**   **+0.31**                   **0.074[^d^](#TN17){ref-type="table-fn"}**   **Yes**                               **+0.28**                                                        **0.002**
  alic_b\_fa                  Anterior limb of the internal capsule, fractional anisotropy, bilateral mean   25(OH)D                   \_\_          \(185\)     +0.0006                                       (0.0002)         9.7e-04       +0.29                       0.12[^d^](#TN17){ref-type="table-fn"}        No                                    +0.22                                                            0.005
  mcp_b\_tr                   Middle cerebellar peduncle, mean diffusivity, bilateral mean                   B-12                      \_\_          \(240\)     −1.45e-07                                     (4.81e-08)       2.8e-03       −0.19                       0.22                                         No                                    −0.18                                                            0.019
  mfowm_b\_tr                 Middle Fronto-Orbital WM, mean diffusivity, bilateral mean                     FOL                       **\_\_**      \(240\)     −5.68e-06                                     (1.93e-06)       3.7e-03       −0.19                       0.22                                         No                                    −0.23                                                            0.019
  cgh_b\_fa                   Cingulum (Hippocampus), fractional anisotropy, bilateral mean                  25(OH)D                   **\_\_**      \(185\)     +0.0006                                       (0.0002)         3.9e-03       +0.25                       0.22                                         No                                    +0.21                                                            0.023
  icp_b\_fa                   Inferior cerebellar peduncle, fractional anisotropy, bilateral mean            FOL                       **\_\_**      \(240\)     +0.0009                                       (0.0003)         4.5e-03       +0.19                       0.22                                         No                                    +0.22                                                            0.015
  ss_b\_fa                    Sagittal Stratum, fraction anisotropy, bilateral mean                          25(OH)D                   **\_\_**      \(185\)     +0.0004                                       (0.0002)         4.9e-03       +0.25                       0.22                                         No                                    +0.20                                                            0.010
  mowm_b\_tr                  Middle Occipital WM, mean diffusivity, bilateral mean                          FOL                       \_\_          \(240\)     −4.13e-06                                     (1.50e-06)       6.5e-03       −0.18                       0.22                                         No                                    −0.17                                                            0.024
  put_b\_tr                   Putamen, mean diffusivity, bilateral mean                                      FOL                       \_\_          \(240\)     −4.22e-06                                     (1.54e-06)       6.5e-03       −0.18                       0.22                                         No                                    −0.26                                                            0.004
  **STRATIFIED**                                                                                                                                                                                                                                                                                                                                                                                                              
  alic_b\_fa                  Anterior limb of the internal capsule, fractional anisotropy, bilateral mean   25(OH)D                   Whites        \(109\)     +0.0009 [^c^](#TN16){ref-type="table-fn"}     (0.0002)         8.6e-05       +0.37                       0.11[^d^](#TN17){ref-type="table-fn"}        No                                    +0.32                                                            0.001
  bcc_b\_tr                   Body of corpus callosum, Mean diffusivity, bilateral mean                      25(OH)D                   BP            \(52\)      −0.00002 [^c^](#TN16){ref-type="table-fn"}    (4.43e-06)       8.7e-05       −0.53                       0.11[^d^](#TN17){ref-type="table-fn"}        No                                    −0.61                                                            0.001
  cgc_b\_fa                   Cingulum (Cingulate Gyrus), fractional anisotropy, bilateral mean              25(OH)D                   Whites        \(109\)     +0.0008                                       (0.0002)         1.1e-04       +0.39                       0.11[^d^](#TN17){ref-type="table-fn"}        No                                    +0.36                                                            \<0.001
  sowm_b\_fa                  Superior Occipital WM, fractional anisotropy, bilateral mean                   FOL                       Males         \(103\)     +0.0016 [^c^](#TN16){ref-type="table-fn"}     (0.0004)         2.1e-04       +0.39                       0.12[^d^](#TN17){ref-type="table-fn"}        No                                    +0.31                                                            0.007
  unc_b\_tr                   Uncinate Fasciculus, mean diffusivity, bilateral mean                          FOL                       AA            \(98\)      2.2e-04[^c^](#TN16){ref-type="table-fn"}      (2.33e-06)       3.4e-04       −0.40                       0.12[^d^](#TN17){ref-type="table-fn"}        No                                    −0.39                                                            0.004
  alic_b\_tr                  Anterior limb of the internal capsule, Mean diffusivity, bilateral mean        FOL                       AP            \(163\)     −6.44e-06                                     1.72e-06         4.6e-04       −0.27                       0.12[^d^](#TN17){ref-type="table-fn"}        No                                    −0.30                                                            0.004
  scc_b\_tr                   Splenium of Corpus Callosum, Mean diffusivity, bilateral mean                  25(OH)D                   BP            \(52\)      −0.000015 [^c^](#TN16){ref-type="table-fn"}   (3.80e-06)       3.0e-04       −0.50                       0.12[^d^](#TN17){ref-type="table-fn"}        No                                    −0.63                                                            0.001
  sowm_b\_tr                  Superior Occipital WM, mean diffusivity, bilateral mean                        FOL                       Males         \(103\)     −0.00001[^c^](#TN16){ref-type="table-fn"}     (3.53e-06)       4.6e-04       −0.37                       0.15[^d^](#TN17){ref-type="table-fn"}        No                                    −0.38                                                            \<0.001
  alic_b\_tr                  Anterior limb of the internal capsule, Mean diffusivity, bilateral mean        FOL                       \>50 years    \(96\)      −0.00001[^c^](#TN16){ref-type="table-fn"}     (2.92e-06)       2.8e-04       −0.36                       0.15[^d^](#TN17){ref-type="table-fn"}        No                                    −0.44                                                            0.011
  cgc_b\_fa                   Cingulum (Cingulate Gyrus), fractional anisotropy, bilateral mean              25(OH)D                   BP            \(52\)      +0.00150                                      0.00040          5.8e-04       +0.57                       0.17[^d^](#TN17){ref-type="table-fn"}        No                                    +0.59                                                            0.003

*25(OH)D, 25-hydroxyvitamin D; AP, Above poverty; B-12, serum cobalamin (vitamin B-12); FOL, serum folate; FWER, FamilyWise Error Rate; GM, Gray Matter; SA, Sensitivity Analysis; SE, Standard Error; WM, White Matter*.

*Values are adjusted linear regression coefficients β with associated SE, standardized beta, uncorrected p-values, corrected q-values (false discovery rate) and results of sensitivity analysis. (N) is the sample size in each analysis. Bolded rows correspond to statistically significant associations after correction for multiple testing, FWER \<0.05*.

*Based on a sensitivity analysis further adjusting for selected socio-demographic, lifestyle and health-related factors after screening using machine learning techniques (see [Supplemental Methods 2](#SM1){ref-type="supplementary-material"}). Note that for visit 1 25(OH)D, no additional covariates were selected. For Folate and B-12 a reduced set of additional covariates were included and are listed in [Supplemental Methods 2](#SM1){ref-type="supplementary-material"}*.

*P \< 0.10 for null hypothesis that exposure × stratifying variable 2-way interaction term is =0 in the unstratified model with exposure and socio-demographic factors included as main effects*.

*Finding considered a trend for passing FDR q-value correction at type I error of 0.10 per vitamin, model and stratification status while failing the FWER criterion, due to a standardized effect size (in absolute value) ≥0.20*.

[Figure 2](#F2){ref-type="fig"} highlights the strongest effect sizes and their associated uncorrected *p*-values observed in the dMRI analysis (Model D), through a series of volcano plots applied to the overall study sample, applied to v~1~ exposures. Effect sizes and direction were also visualized on standard ROI-specific brain images, for associations with *p*~uncorr~ \< 0.05.

Discussion {#s4}
==========

This study is among few that used a brain scan-wide analysis methodology to test associations of serum 25(OH)D, folate and cobalamin with brain volumes and WMI and the first to do so among socio-demographically diverse adults. The 3 vitamin status measures were systematically correlated with sMRI/dMRI brain markers, from low-to-high segmentation levels. We found statistically significant (FWER \< 0.05) direct associations of 25(OH)D(v~1~) with total, occipital and parietal WM volumes, particularly among men and older participants and with left occipital pole volume, overall and among individuals living above poverty. The latter findings were replicated for 25(OH)D (v~2~-v~1~). Only trends were detected for cobalamin exposures (*q* \< 0.10), while serum folate (v~1~) was associated with lower mean diffusivity (MD) in ALIC, reflecting greater WMI, overall.

In terms of 25(OH)D and sMRI markers, vitamin D deficiency appears to be associated with smaller hippocampal subfields in MCI participants (Karakis et al., [@B45]; Al-Amin et al., [@B1]). Our study indicated that 25(OH)D was inversely linked to WM volumes, particularly in the left occipital pole. The occipital pole encompasses the primary visual cortex and contributes to language abilities (Charles et al., [@B21]; Melrose et al., [@B54]). Decline in verbal fluency has been related to lower 25(OH)D status (Beydoun et al., [@B11]; Goodwill et al., [@B36]). Relations of vitamin D deficiency with smaller WM volumes and poorer integrity were shown elsewhere (Buell et al., [@B17]; Prager et al., [@B63]; Annweiler et al., [@B3]; Del Brutto et al., [@B26]). Vitamin D status was also associated with larger GM volumes (Brouwer-Brolsma et al., [@B15]), smaller ventricles (Annweiler et al., [@B5]) or not related to brain markers (Michos et al., [@B55]; Littlejohns et al., [@B50]). Our race-specific associations are notable, possibly due to genetic polymorphisms determining brain vitamin D status, which pending further studies, may be higher among Whites compared to AAs (Powe et al., [@B62]; Berg et al., [@B7]).

Among comparable ROI-specific dMRI studies, a cross-sectional study (Moon et al., [@B58]), found an inverse association between 25(OH)D and FA values near the inferior and superior longitudinal fasciculi, corpus callosum (genu), the anterior corona radiata, the ALIC and the cingulum bundle. Most regional FAs, particularly the ALIC and cingulum bundle (cingulate and hippocampus), were found to be positively associated with 25(OH)D in our study. These associations were statistically significant for annual rates of change in 25(OH)D, specifically for ALIC and the hippocampus.

Similarly, folate and cobalamin were previously linked to larger brain volumes (or slower atrophy), specifically within hippocampal and amygdala regions (Scott et al., [@B70]; Vogiatzoglou et al., [@B80]; Lee et al., [@B49]) and reduced WM lesion severity (De Lau et al., [@B24]; Pieters et al., [@B61]). In our study, cobalamin was related to occipital and temporal GM volumes, an association that was attenuated with full covariate-adjustment. B-6 and cobalamin intakes were also shown to spare GM atrophy, with specific association between cobalamin status and bi-lateral superior parietal sulcus (Erickson et al., [@B32]). Moreover, direct relationship between cobalamin status and regional GM volume (right precuneus, right post-central gyrus and left inferior parietal lobule) in AD was found mostly among ApoE4+ individuals (Lee et al., [@B49]). Our study showed a trend between increasing levels of cobalamin and larger parts of the inferior frontal gyrus \[orbital (left); triangular (right)\], known for its function in processing speech and language (Greenlee et al., [@B37]). A longitudinal study of adults found that lower cobalamin status, but not folate, was linked to increased rate of brain volume loss. A recent trial (VITACOG) conducted among MCI patients showed that GM regions vulnerable to AD, such as the medial temporal lobe, benefited from high-dose B vitamin supplementation by slowing atrophy rates over 2 years, though this pertained only to hyperhomocysteinemic individuals (Douaud et al., [@B30]), and this trial indicated that B vitamin supplementation can stabilize executive functions and reduce decline in global cognition, episodic and semantic memory (De Jager et al., [@B23]).

Novel are our findings that folate and 25(OH)D are inversely related to MD while being directly associated with FA, particularly in the ALIC region. This is corroborated by a direct association between annual 25(OH)D increase and ALIC volumes at follow-up. While previous studies have linked vitamin D and folate deficiency to WM damage (Sachdev et al., [@B68]; Bleich and Kornhuber, [@B13]; Den Heijer et al., [@B27]; Dufouil et al., [@B31]; Scott et al., [@B70]; Censori et al., [@B19]; De Lau et al., [@B24]; Pieters et al., [@B61]; Buell et al., [@B17]; Prager et al., [@B63]; Annweiler et al., [@B3]; Del Brutto et al., [@B26]; Moon et al., [@B58]; Wu et al., [@B85]; Lee et al., [@B48]), our study further specified most affected ROIs and target socio-demographic groups. The ALIC connects the thalamus with the frontal lobe, suggesting these nutrients can maintain cognitive functions that are reliant on frontothalamic connectivity, such as executive function (Schoenberg and Scott, [@B69]; Jacobs et al., [@B40]). Despite folate not being consistently associated with executive function or attention (Rosenberg, [@B67]), it was inversely related to depression (Bender et al., [@B6]) and reduced ALIC FA prevails in depressive disorders (Zou et al., [@B86]; Jia et al., [@B43]; Chen et al., [@B22]). Moreover, depressive symptoms increase dementia risk (Tan et al., [@B76]). Thus, future studies could explore mediation of the depression-AD relationship through ALIC FA and MD as the mechanism for folate supplementation prevention.

Our findings indicate that in certain sub-groups, folate may adversely affect volumetric markers, specifically the right temporal pole volume, thought to contribute to personal and episodic memories, also shown to be linked with empathy (Rankin et al., [@B65]). The literature shows an interaction between folate and cobalamin status, whereby high folate status coupled with cobalamin deficiency was associated with smaller GM volumes in the right middle occipital gyrus and the opercular part of the inferior frontal gyrus (Deng et al., [@B28]). Thus, abnormally high levels of folate may relate to poorer outcomes, though this finding may be spurious and due to chance, requiring replication in a larger meta-analytic studies.

Our study has several notable strengths. First, it examined the association between several AD-related nutritional biomarkers with brain structural sMRI and dMRI measures reflecting regional volumes and WMI, potentially underlying various neuropathologies. Moreover, while cross-sectional, this study provided 5--6 years of latency between exposure (nutritional biomarkers) and outcome (brain MRI measures) and secondarily tested associations between exposure trajectories and follow-up outcomes, with stratum-specific heterogeneity and adjusting for multiple testing. Additionally, given that serum 25(OH)D was recently linked to lower intracranial volume (ICV) (Annweiler et al., [@B2]), our detected positive association between 25(OH)D and brain volumes, including WM, may be conservative and under-estimated, and may be inflated upon ICV adjustment.

Nevertheless, study findings should be interpreted with caution given limitations. First, due to dMRI voxel size limitations, partial volume effects and possible contamination by nearby cerebral spinal fluid can occur, increasing FA and MD estimation errors. Second, timing of blood sample collection and measurement errors may have affected the sample distribution of serum 25(OH)D levels, with overestimation as a possibility as 10%-15% of the measured 25(OH)D values are in fact 24,25-dihydroxyvitamin D, which is recognized by the same antibody. Third, the 25(OH)D assay in HANDLS was measured using two different methodologies at v~1~ and v~2~. Thus, our sensitivity analyses may be biased due to exposure measurement error. The moderate correlation between visits in 25(OH)D (*r* = 0.44) suggests a minimal error, though inter-assay comparisons are needed. Fourth, the latency between exposure and outcome could make the findings somewhat speculative when compared to a cohort study whereby baseline exposure is being tested against annualized change in outcome. The lack of a baseline sMRI/dMRI measure is a notable limitation of this study that should be remedied in further studies of comparable populations. Other potential limitations include the lack of other related serum measures, such as Hcy and vitamin B-6 in HANDLS, the lack of longer term markers, such as red blood cell folate, residual confounding particularly by physical activity which was not adequately measured at v~1~ and v~2~, non-participation selection bias, and a lower powered stratum-specific associations especially by race and poverty status. Due to differences in dietary intakes, absorption, utilization, distribution or other confounding conditions, circulating levels of target vitamins may not reflect their brain tissue levels, reducing their value as biomarkers. Moreover, our strongest findings implicate 25(OH)D as the main exposure, which may confound the association of serum folate with region-specific WMI. A larger meta-analytic study may be needed to disentangle those associations. Finally, external validity may be limited to inner US cities with similar racial/ethnic and socio-economic diversity as Baltimore City, as well as to middle-aged adults.

In summary, serum 25(OH)D status and increase were consistently linked to larger occipital and parietal WM volumes. WMI in ALIC and cingulum (hippocampus) were significantly associated with faster increase in 25(OH)D over time. Pending longitudinal replication of our findings, future interventions should test vitamin D supplementation against regional volumetric and diffusion brain markers and mechanistic studies are needed to examine regional vulnerability to vitamin status.
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:   Core for Translational Research in Imaging @ Maryland

DTI, Diffusion Tensor Imaging, dMRI

:   Diffusion MRI
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:   Fractional Anisotropy

FWER, Familywise Error Rate, FDR
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FLAIR

:   Fluid-Attenuated Inversion Recovery

FOV

:   Field of View
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:   Gray Matter

HANDLS

:   Healthy Aging in Neighborhoods of Diversity across the Life Span study
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MRI

:   Magnetic Resonance Imaging
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:   Mean Diffusivity
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OCM
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